Amneal Pharma Faces Parkinson's Candidate Setback with FDA's CRL
- July 03rd, 2023
- 407 views
Shares of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) dropped over 10% in after-hours trading due to a Complete Response Letter from the FDA regarding the company's New Drug Application for IPX203 to treat Parkinson's disease, a neurological condition characterized by involuntary and uncontrolled movements, including tremors, rigidity, and challenges with balance and coordination.
According to Amneal, the FDA requested additional information on the ingredient carbidopa, and no issues were identified in the letter regarding the efficacy or manufacturing of IPX203.
The company stated that it will work with the FDA to address the comments and move forward, and the financial guidance for 2023 remains unaffected by this development.
$AMRX was trading at $2.65 (-13.11%) in the extended session after the announcement.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login